Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Voxelotor in sickle cell nephropathy
NCT04335721Phase 2Terminated
- Sponsor
- University of Illinois Chicago
- Start
- Mar 2021
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in sickle cell anemia (SCA) comparing Voxelotor with Standard of Care (2 arms). Primary endpoint: Change in albuminuria at 48 weeks. Started Mar 2021; status: terminated.
02
Drugs
voxelotor
03
Conditions
sickle cell anemia (SCA)
Beyond the preview
Go deeper on NCT04335721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04335721.